Month: May 2018

Article: Lexington Biosciences is Set to Help Predict Cardiovascular Disease

Lexington Biosciences Inc. (CSE:LNB) (OTC:LXGTF) plans to commercialize an at-home product to better predict whether a person is at risk for cardiovascular disease Angela Harmantas | May 31, 2018 | SmallCapPower: Cardiovascular disease is leading cause of death in North America, and yet, nearly one-third of those deaths are preventable. Annually, over 1.5 million people

Read More

VIDEO: Lexington Biosciences Founder: We Have a Cardiovascular Disease Prediction Device

Lexington Biosciences, Inc.’s (CSE:LNB) Donald McInnes discusses the Company’s regulatory and commercialization efforts Lexington Biosciences Founder: We Have a Cardiovascular Disease Prediction Device In an interview with SmallCapPower, Lexington Biosciences, Inc. (CSE:LNB) Founder and Board Advisor Donald McInnes explains that Lexington’s technology helps predict cardiovascular disease, which is known as the “silent killer.” Find out more about

Read More

Lexington Biosciences Digital Newsletter V1

The Wellness Sector Revolution and HeartSentry by Lexington Bioscience Dear Friends and Shareholders, Today, the Lexington Biosciences team is bringing together some items and articles of interest all in one location in order to inform and educate about an extraordinary story going on around us. Some of you may already know all about our company,

Read More

Lexington Engages with Major Canadian University and Provides Clinical Trial Update

Company commences HeartSentry clinical research collaboration with University of British Columbia VANCOUVER, British Columbia, May 08, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to advise it has engaged with a dedicated research team at The University of British Columbia (“UBC”) to perform an independent analysis and

Read More

Lexington Announces Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, B.C., May 04, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”) is pleased to announce that it has appointed Gravitas Securities Inc. and Canaccord Genuity Corp. (collectively, the “Agents”) to sell, by way of a private placement on a best efforts

Read More



Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News